NCT06039449 - A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2 | Biotech Hunter

Enrollment

790

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

November 19, 2024

Study Completion Date

November 19, 2024

Conditions

COVID-19SARS-CoV-2

Interventions

DRUG

VYD222 (pemivibart)

Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.

DRUG

Normal saline

Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.

Trial Locations (18)

20904

INVIVYD Investigative Site, Silver Spring

27560

INVIVYD Investigative Site, Morrisville

28144

INVIVYD Investigative Site, Salisbury

30328

INVIVYD Investigative Site, Atlanta

31313

INVIVYD Investigative Site, Hinesville

33186

INVIVYD Investigative Site, Miami

33705

INVIVYD Investigative Site, St. Petersburg

33756

INVIVYD Investigative Site, Clearwater

60523

INVIVYD Investigative Site, Oak Brook

73013

INVIVYD Investigative Site, Edmond

73099

INVIVYD Investigative Site, Yukon

75230

INVIVYD Investigative Site, Dallas

77706

INVIVYD Investigative Site, Beaumont

90274

INVIVYD Investigative Site, Rolling Hills Estates

90806

INVIVYD Investigative Site, Long Beach

92103

INVIVYD Investigative Site, San Diego

92835

INVIVYD Investigative Site, Fullerton

01803

INVIVYD Investigative Site, Burlington